The U.S. Food and Drug Administration (FDA) has cleared software developer Icometrix's new software for diagnosing dementia using brain MRI scans.
Icobrain dm provides reports and color-coded brain images to help clinicians monitor brain volume changes in dementia patients. It joins the company's existing software, icobrain ms, which helps clinicians treat multiple sclerosis patients, and icobrain tbi, which helps track injuries in head trauma patients.
